Based on the expression of specific biomarkers including ER, progesterone receptor (PR) and HER2, BC has been classified into at least four clinically relevant subtypes, including luminal A, luminal B, HER2-enriched, and basal like subtype. This evidence concerns the gene ERBB2 and breast cancer.